AC Immune (NASDAQ:ACIU) Announces Quarterly Earnings Results

AC Immune (NASDAQ:ACIU) posted its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06, FiscalAI reports. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The firm had revenue of $3.88 million for the quarter, compared to the consensus estimate of $0.33 million.

AC Immune Stock Performance

ACIU stock traded up $0.17 during mid-day trading on Wednesday, hitting $2.25. The company had a trading volume of 155,504 shares, compared to its average volume of 265,633. The firm has a market cap of $229.49 million, a PE ratio of -4.18 and a beta of 1.64. AC Immune has a 12 month low of $2.02 and a 12 month high of $3.90. The stock’s fifty day moving average price is $2.58 and its two-hundred day moving average price is $2.72.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Wednesday, September 23rd. Zacks Research cut shares of AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. Finally, HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.50.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.